Lead Product(s) : EM-221
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears IND For EuMentis’ EM-221 PDE10A Inhibitor In Schizophrenia
Details : EM-221 is targeting PDE10A, a key intracellular enzyme that regulates dopamine and glutamate signaling in brain regions implicated in schizophrenia.
Product Name : EM–221
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 30, 2025
Lead Product(s) : EM-221
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
